Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 11 (Table of Contents)
Published: 26 Nov-2013
DOI: 10.3833/pdr.v2013.i11.1993 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to attain a dominant position in the hereditary angioedema (HAE) market and to increase the size of its rare disease business unit, Shire has agreed to acquire ViroPharma for approximately US$4...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS